Nesta Clinic
Istanbul, Sisli, 34349, Turkey (Türkiye)
Location contact
Seyma Aydiner, B.B.A
CONTACT
Zuhal Yucel, B.N.
CONTACT
NCT Number: NCT06396390
The goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: Progestin Primed Ovarian Stimulation (PPOS) vs. GnRH Antagonist in embryologic outcomes of IVF Patients.
Trial opening soon.
Get Notified18 year–45 year
Female
Interventional
Phase 4
Istanbul, Sisli, 34349, Turkey (Türkiye)
Seyma Aydiner, B.B.A
CONTACT
Zuhal Yucel, B.N.
CONTACT
The goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: Progestin Primed Ovarian Stimulation (PPOS) vs. GnRH Antagonist in embryologic outcomes of IVF Patients.
Ovarian stimulation will be conducted according to the assigned arm protocol.
Both artificially prepared and modified natural cycles will be eligible to be included and the choice will be done according to the doctor's preference and the patient's menstrual cycle regularity.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Other names: Progestin Primed Ovarian Stimulation Protocol
In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Other names: GnRH Antagonist Ovarian Stimulation Protocol
Time frame: Day 5 or 6 after fertilization
number of blastocysts up to day 6 / the number of fertilized 2PN embryos
Time frame: 14 days after blastocyte culture sampling
Euploidy and aneuploidy rates
Time frame: on gestational week 12
Fetal heart rate examination via USG
Time frame: 9 months
For pregnancies resulted within the study period, live birth/embryo transfer count
Time frame: on day 11 after transfer
Serum ß-hcg level
Contact information is provided by the study sponsor or research team.
Nesta Clinic
Network
The Comparative Results of Progestin Primed Ovarian Stimulation (PPOS) and GnRH Antagonist Ovarian Stimulation Methods on IVF Outcomes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04381299
Adnexal Diseases, Anti-Mullerian Hormone Deficiency
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
View Trial DetailsNCT05500573
Genital Diseases, IVF
New York, United States
View Trial DetailsNCT07480668
Anxiety, Anxiety Disorders
Belo Horizonte, Minas Gerais, Brazil
View Trial DetailsNCT07499817
Embryo Transfer, Genital Diseases
Banī Suwayf, Beni Suweif Governorate, Egypt
View Trial Details